Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Research ID

hum0292-v1Release info

Latest

Research title

Development of blood-based biomarkers for precision medicine in castration-resistant prostate cancer

Research overview

Aims
To develop predictive biomarkers for the treatment of castration-resistant prostate cancer (CRPC) such as abiraterone, enzalutamide, docetaxel, and cabazitaxel based on genomic analyses of cell-free DNA (cfDNA) and circulating tumor cells (CTC).
Methods
One hundred CRPC patients eligible for treatment with either abiraterone or enzalutamide were prospectively enrolled at 17 institutions in Japan. cfDNA and paired lymphocyte DNA per patient were used for sequencing library preparation, and unique molecular identifiers were added. Targeted sequencing was performed using Illumina NovaSeq (Our custom gene panel captures the exonic regions of 88 genes).
Participants/materials
100 CRPC patients eligible for abiraterone or enzalutamide
URL
N/A

Datasets

CartDataset IDType of dataAnalysis methodAccess criteriaDate published
JGAD000441NGS (Target Capture)
  • Targeted DNA sequencing
Controlled-access (Type I)2021-09-17

Data provider

Principal investigator
Shusuke Akamatsu
Affiliation
Department of Urology, Graduate School of Medicine, Kyoto University

Research projects

No research projects.

Grants

NameTitleProject number
KAKENHI Grant-in-Aid for Scientific Research (B)
Understanding the biological mechanisms of defective DNA damage repair in prostate cancer using cell-free DNA analysis
  • 20H03814
AstraZeneca Externally Sponsored Scientific Research
The prevalence of germline and somatic DNA repair gene mutations in Japanese prostate cancer patients
  • NCR-17-13159
Astellas Research Grant
Identification of factors predicting response to enzalutamide using tissues of castration-resistant prostate cancer
N/A

Related publications

TitleDOIDataset ID
Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer
https://doi.org/10.1158/1078-0432.CCR-21-2328 (opens in a new tab)

Controlled access users

No use of the controlled access data has been recorded.